Gossamer Bio, Inc. (GOSS)

CIK 0001728117 · Healthcare · Biotechnology

Recent Filing Index

Form Filed Qtr End F_Period 8K: Earnings Release
— Q2-2026 8-K (2026-07-27) · 99.1
— 8-K (2026-05-18) · 99.1 · 99.2
Latest Q1-2026 —
Latest FY-2025 8-K (2026-03-17) · 99.1
Q3-2025 8-K (2025-11-05) · 99.1
Q2-2025 8-K (2025-08-05) · 99.1
Q1-2025 8-K (2025-05-15) · 99.1
FY-2024 8-K (2025-03-13) · 99.1
Q3-2024 8-K (2024-11-07) · 99.1
Q2-2024 8-K (2024-08-12) · 99.1
Q1-2024 8-K (2024-05-07) · 99.1
FY-2023 8-K (2024-03-05) · 99.1
Q3-2023 8-K (2023-11-09) · 99.1
Q2-2023 8-K (2023-08-08) · 99.1

Filing Summary

Report Name | Notes Fiscal Period (Annual) Fiscal Period (Quarter)
Cover
Audit Information
—
Statements
Consolidated Balance Sheets
Consolidated Balance Sheets (P)
Consolidated Statements of Operations and Comprehensive Loss
Consolidated Statements of Stockholders Equity (deficit)
Consolidated Statements of Cash Flows
Consolidated Statements of Stockholders' Equity
—
Consolidated Statements of Stockholders Equity (deficit) (P)
Consolidated Statements of Stockholders' Equity (P)
—
Notes
Accrued Expenses and Other Current Liabilities
—
Balance Sheet Accounts and Supplemental Disclosures
—
Commitments and Contingencies
Cybersecurity Risk Management and Strategy Disclosure
—
Description of Business
Equity Incentive Plans
Fair Value Measurements and Available For Sale Investments
Income Taxes
Indebtedness
Insider Trading Arrangements
Insider Trading Policies and Procedures
—
Investments In Variable Interest Entities
Licenses, Asset Acquisitions and Contingent Consideration
Pay Vs Performance Disclosure
Property and Equipment, Net
—
Segment Information
Segment Reporting
—
Significant Agreements and Contracts
Stockholders Equity (deficit)
—
Stockholders' Equity
Subsequent Events
Summary of Significant Accounting Policies